Exeter, UK, 01-Dec-2016 — /EuropaWire/ — The first licensed vaccine for the potentially life-threatening dengue virus should only be used in moderate-to high impacted regions, new research has predicted. A team of international researchers, including Dr Mario Recker from the University … Read the full press release
Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Dengue, Dengue Vaccine, Dengvaxia®, Sanofi, Sanofi Pasteur
– The highest burden of dengue disease globally in endemic countries is in pre-adolescent to adults age group[1],[2],[3] – In a new pooled analysis, dengue vaccine candidate protected two out of three volunteers aged 9 years and older against all four … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Dengue Vaccine, Dr. Maria Rosario, New England Journal of Medicine, Sanofi Pasteur
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
